The participation in this initiative is in addition to the introduction of the EarlyCDT-Lung Test of the biotechnology company located at the University of Valencia Science Park (PCUV) in the health systems of Galicia, Aragon, Castilla-La Mancha and Andalusia
Promoted by the Galician General Directorate of Public Health, belonging to the Regional Ministry of Health, the Inspira Saúde Plan is a multidisciplinary initiative focused on tackling the problem of smoking in Galicia. The strategic lines presented in the plan are aimed at reducing the prevalence of addiction to tobacco consumption, supporting those who wish to quit smoking, creating smoke-free environments and promoting the early detection of lung cancer and other diseases caused by tobacco consumption.
One of the main strategic lines of the Inspira Saúde Plan focuses on the early detection of the main diseases related to tobacco consumption, with special emphasis on lung cancer. In this sense, the aim is to advance in the development of new strategies for the early detection of smoking-related diseases by means of different actions.
Responding to this objective, the biotechnology company Sabartech, located in the Science Park of the University of Valencia (PCUV), highlights its contribution in the implementation of a completely innovative action, which consists of the implementation and validation of liquid biopsy techniques and/or autoantibodies in patients with lung nodules detected in order to optimize interventional diagnostic strategies and radiological follow-up. In this context, Sabartech's EarlyCDT-Lung Test serves as an autoantibody screening test to carry out this action.
One of the main strategic lines of the Inspira Salud Plan focuses on the early detection of the main diseases related to tobacco consumption, with special emphasis on lung cancer
The test has already been introduced and coded in the Servizo Galego de Saúde (SERGAS), and in the healthcare systems of other autonomous communities such as Aragón, Castilla-La Mancha and Andalusia. It is also in the process of being introduced in Madrid, Asturias and also in the Canary Islands.
The company expects to expand the availability of the EarlyCDT-Lung test in the rest of the Spanish healthcare systems, with the aim of providing wider early detection and timely treatment to improve the quality of life of a greater number of patients.
"Sabartech, with the work carried out since 2018 for the introduction of EarlyCDT-Lung in Spanish public healthcare, is proud of its contribution in the Plan and early detection of lung cancer. We hope to expand the availability of the EarlyCDT-Lung test in the rest of Spanish healthcare systems, with the aim of providing wider early detection and timely treatment to improve the quality of life of patients," highlights Javier Sarasqueta, CEO of this biotech company.
The Sabartech test has already been introduced in the Servizo Galego de Saúde (SERGAS) and has been codified in the healthcare systems of Aragón, Castilla-La Mancha and Andalusia. It is also in the process of being introduced in Madrid, Asturias and also in the Canary Islands.